ArticleJAMA network open2022

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.

Samer Al Hadidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.